基本信息 产品详情 公司简介 推荐产品
  • 首页
  • 个人中心
  • 委托采购
  • 采购清单
网站主页 阿莫奈韦 阿莫奈韦
  • 阿莫奈韦|T4226|TargetMol

阿莫奈韦|T4226|TargetMol

Amenamevir
841301-32-4
￥396 1mg 起订
￥993 5mg 起订
￥1570 10mg 起订
上海 更新日期：2024-09-29

TargetMol中国（陶术生物）

VIP3年
联系人：邵小姐
手机：4008200310 拨打
邮箱：marketing@tsbiochem.com

产品详情:

中文名称：
阿莫奈韦
英文名称：
Amenamevir
CAS号：
841301-32-4
品牌：
TargetMol
产地：
美国
保存条件：
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
纯度规格：
99.86%
产品类别：
抑制剂
货号：
T4226

Product Introduction

Bioactivity

NameAmenamevir
DescriptionAmenamevir (ASP2151) is a novel helicase-primase inhibitor that is active against varicella-zoster virus and herpes simplex virus types 1 and 2 (EC50: 14 ng/mL).
Cell ResearchThe antiviral activities of Amenamevir and ACV against HSVs are tested using a plaque reduction assay. Briefly, HEF cells are seeded into multi-well plates and incubated until they form a monolayer. After the medium is removed, the cells are infected with HSV-1 or HSV-2, and the plates are further incubated for 1 h at 37°C. The cells are washed twice with maintenance medium and then treated with the test compound (including Amenamevir) until clear plaques appear. The cells are then fixed with 10% formalin in phosphate-buffered saline, stained with a 0.02% crystal violet solution, and the number of plaques is determined under a light microscope. The EC50, which represents the concentration of test compound needed to reduce the plaque number by 50%, is calculated using nonlinear regression analysis with a sigmoid-maximum effect (Emax) model[1].
Animal ResearchFemale hairless mice (HOS: HR-1, 7 to 8 weeks old) are infected with a suspension of HSV-1 strain WT51 (15 μL/mouse; titer, 2×108 PFU/mL) or CI-116 (15 μL/mouse; titer, 4×107 PFU/mL) in the dorsolateral skin stripped as a small square using a needle, under anesthesia. The day of HSV-1 infection is designated day zero postinfection. Total daily doses of 1, 3, 10, 30, or 100 mg/kg/day ASP2151 are orally administered to HSV-1-infected mice (n=5) for 5 days. Amenamevir (ASP2151) treatments are started 2 to 3 h after HSV infection either as a single daily dose (every 24 h, q24h) or as two (every 12 h, q12h) or three (every 8 h, q8h) divided doses. Lesion scores and intradermal HSV-1 titers are measured on day 5 postinfection[1].
In vitroAmenamevir对HSV-1和HSV-2的平均EC50分别为14 ng/mL（范围7.7-20）和30 ng/mL（范围15-58），而Acyclovir（ACV）的相应值分别为29 ng/mL（范围18-38）和71 ng/mL（范围45-95）。
In vivoAmenamevir（ASP2151, 3-30 mg/kg/day）以剂量依赖性方式加速病毒滴度的减少，不论给药间隔如何，均可剂量依赖性降低HSV-1滴度和病损评分。根据相关性曲线，Amenamevir（口服）能完全抑制HSV-1的生长，并估算出以下药动学参数：血清中Cmax达到或超过10,000 ng/mL；AUC24h达到或超过60 μg·h/ml；T>100保持时间为21至24小时。感染后第5天，Amenamevir在血浆中的平均浓度随剂量增加而升高，3 mg Amenamevir/g或更高剂量显著降低了皮内HSV-1的滴度。
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility InformationDMSO : 15 mg/mL (31.08 mM)
KeywordsHerpes simplex virus | Inhibitor | ASP-2151 | Amenamevir | ASP 2151 | HSV | inhibit
Inhibitors RelatedGuanidine hydrochloride | Thymidine
Related Compound LibrariesInhibitor Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Aging Compound Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Drug Library
阿莫奈韦|||ASP2151|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期 (12年)
注册资本 566.265100万人民币
员工人数 100-500人
年营业额 ￥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

阿莫奈韦相关厂家报价

内容声明
official 进入官方账号
拨打电话 立即询价